Biblio
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis. Blood. 2023.
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges. Ther Adv Hematol. 2023;14:20406207231177282.
. Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019.